498 related articles for article (PubMed ID: 30528938)
1. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S
Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N
Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605
[TBL] [Abstract][Full Text] [Related]
3. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.
Avogbe PH; Manel A; Vian E; Durand G; Forey N; Voegele C; Zvereva M; Hosen MI; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Delhomme TM; Carreira C; Monteiro-Reis S; Henrique R; Abedi-Ardekani B; Byrnes G; Foll M; Weiderpass E; McKay J; Jeronimo C; Scelo G; Le Calvez-Kelm F
EBioMedicine; 2019 Jun; 44():431-438. PubMed ID: 31122840
[TBL] [Abstract][Full Text] [Related]
4. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
5. Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification.
Ward DG; Gordon NS; Boucher RH; Pirrie SJ; Baxter L; Ott S; Silcock L; Whalley CM; Stockton JD; Beggs AD; Griffiths M; Abbotts B; Ijakipour H; Latheef FN; Robinson RA; White AJ; James ND; Zeegers MP; Cheng KK; Bryan RT
BJU Int; 2019 Sep; 124(3):532-544. PubMed ID: 31077629
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
[TBL] [Abstract][Full Text] [Related]
7. TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region.
Pakmanesh H; Anvari O; Forey N; Weiderpass E; Malekpourafshar R; Iranpour M; Shahesmaeili A; Ahmadi N; Bazrafshan A; Zendehdel K; Kannengiesser C; Ba I; McKay J; Zvereva M; Hosen MI; Sheikh M; Calvez-Kelm FL
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430798
[TBL] [Abstract][Full Text] [Related]
8. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer.
Hayashi Y; Fujita K; Matsuzaki K; Eich ML; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Netto GJ; Nonomura N
Front Oncol; 2020; 10():755. PubMed ID: 32509577
[TBL] [Abstract][Full Text] [Related]
10. Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers.
Lin SY; Linehan JA; Wilson TG; Hoon DSB
Eur Urol Focus; 2017 Apr; 3(2-3):265-272. PubMed ID: 28753876
[TBL] [Abstract][Full Text] [Related]
11. Detection of TERT promoter mutation in serum cell-free DNA using wild-type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma.
Akuta N; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Suzuki Y; Kumada H
J Med Virol; 2020 Dec; 92(12):3604-3608. PubMed ID: 32100879
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR.
Wang K; Liu T; Ge N; Liu L; Yuan X; Liu J; Kong F; Wang C; Ren H; Yan K; Hu S; Xu Z; Björkholm M; Fan Y; Zhao S; Liu C; Xu D
Oncotarget; 2014 Dec; 5(23):12428-39. PubMed ID: 25474136
[TBL] [Abstract][Full Text] [Related]
13. Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study.
Hosen MI; Sheikh M; Zvereva M; Scelo G; Forey N; Durand G; Voegele C; Poustchi H; Khoshnia M; Roshandel G; Sotoudeh M; Nikmanesh A; Etemadi A; Avogbe PH; Chopard P; Delhomme TM; Foll M; Manel A; Vian E; Weiderpass E; Kamangar F; Boffetta P; Pharaoh PD; Dawsey SM; Abnet CC; Brennan P; McKay J; Malekzadeh R; Calvez-Kelm FL
EBioMedicine; 2020 Mar; 53():102643. PubMed ID: 32081602
[TBL] [Abstract][Full Text] [Related]
14. Screening for a practical method to monitor the status of patients with metastatic bladder cancer at the circulating cell-gene level.
Ogura R; Ito S; Ueda T; Gabata Y; Sako S; Inoue Y; Yamada T; Konishi H; Fujihara A; Ukimura O
Sci Rep; 2023 Nov; 13(1):19517. PubMed ID: 37945655
[TBL] [Abstract][Full Text] [Related]
15. Activating Telomerase
Zvereva M; Pisarev E; Hosen I; Kisil O; Matskeplishvili S; Kubareva E; Kamalov D; Tivtikyan A; Manel A; Vian E; Kamalov A; Ecke T; Calvez-Kelm FL
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839402
[TBL] [Abstract][Full Text] [Related]
16. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
Akuta N; Kawamura Y; Kobayashi M; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
Oncology; 2021; 99(2):114-123. PubMed ID: 32998139
[TBL] [Abstract][Full Text] [Related]
17. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors.
Fitzgerald JM; Ramchurren N; Rieger K; Levesque P; Silverman M; Libertino JA; Summerhayes IC
J Natl Cancer Inst; 1995 Jan; 87(2):129-33. PubMed ID: 7707384
[TBL] [Abstract][Full Text] [Related]
18. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer.
Tong L; Ding N; Tong X; Li J; Zhang Y; Wang X; Xu X; Ye M; Li C; Wu X; Bao H; Zhang X; Hong Q; Song Y; Shao YW; Bai C; Zhou J; Hu J
Theranostics; 2019; 9(19):5532-5541. PubMed ID: 31534501
[TBL] [Abstract][Full Text] [Related]
19.
Muralidharan K; Yekula A; Small JL; Rosh ZS; Kang KM; Wang L; Lau S; Zhang H; Lee H; Bettegowda C; Chicoine MR; Kalkanis SN; Shankar GM; Nahed BV; Curry WT; Jones PS; Cahill DP; Balaj L; Carter BS
Clin Cancer Res; 2021 Jan; 27(1):169-178. PubMed ID: 33051308
[TBL] [Abstract][Full Text] [Related]
20. Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary
Hosen MI; Forey N; Durand G; Voegele C; Bilici S; Avogbe PH; Delhomme TM; Foll M; Manel A; Vian E; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Boureille A; Pisarev E; Salas AROSE; Monteiro-Reis S; Henrique R; Byrnes G; Jeronimo C; Scelo G; McKay JD; Calvez-Kelm FL; Zvereva M
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33260905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
